Callaway Golf Company CALY 深 沪
已收盘 02-06 16:00:00 美东时间
15.01
+0.460
+3.16%
华盛通- 最 高15.17
- 今 开15.05
- 成交量 314.96万股
- 最 低 14.74
- 昨 收 14.55
- 总市值 600.40万
- 52周最高 50.65
- 市盈率 静 --
- 换手率 787.40%
- 52周最低 14.06
- 委 比 -38.65%
- 总股本 40.00万
- 历史最高 50.65
- 量 比 1.15
- 振 幅 2.96%
- 历史最低 14.06
- 每 手 1
- 风险率 0.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
This Elanco Animal Health Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Top Wall Street analysts changed their outlook on these top names. For a comple...
01-22 19:35
B. Riley Securities Upgrades Callaway Golf to Buy, Raises Price Target to $19
B. Riley Securities analyst Anna Glaessgen upgrades Callaway Golf (NYSE:CALY) from Neutral to Buy and raises the price target from $11 to $19.
01-22 18:29
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies Jan 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cencora, Crocs and Teledyne Technologies, on Thursday. HIGHLIGHTS * Cencora COR.N : Jefferies raises to b
01-22 15:17
Callaway Golf Introduces Quantum Drivers, Fairway Woods, Irons, and Hybrids
The new Quantum Drivers feature Callaway's revolutionary Tri-Force Face for a leap in distance, while Quantum Irons are engineered for a leap in greens hit CARLSBAD, Calif., Jan. 16, 2026 /P...
01-16 23:00
Topgolf Callaway Brands to Sell 60% of Topgolf for $1.1B, Expects $770M in Net Proceeds From Deal With Leonard Green & Partners
Topgolf Callaway Brands Corp. (the "Company" or "Topgolf Callaway Brands," "we," "our," "us") (NYSE:MODG) today announced that it has signed a definitive agreement to sell a 60% stake in its Topgolf and Toptracer
2025-11-18 19:32
BRIEF-Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
Jan 13 (Reuters) - Kiniksa Pharmaceuticals International PLC KNSA.O: KINIKSA PHARMACEUTICALS INTERNATIONAL PLC - ARCALYST 2024 NET PRODUCT REVENUE $416.4 MILLION, 79% YOY GROWTH KINIKSA PHARMACEUTICAL...
2025-01-13 21:48
